Introduction {#s1}
============

The mammalian transient receptor potential (TRP) superfamily of cation channels has six subfamilies, including the vanilloid (TRPV), canonical (TRPC), melastatin (TRPM), ankyrin (TRPA), polycystin (TRPP), and mucolipin (TRPML) subfamilies, which are separated based on sequence homology ([@B94]). Also known as ATKTM1, the TRPA1 channel represents the sole member of the TRPA subfamily and contains six transmembrane domain (S1--S6) polypeptide subunits. Its name is derived from the unusually high number of ankyrin repeats within the N-terminus and the pore-forming selectivity filter positions between the S5 and S6 transmembrane segments ([@B85]; [@B66]). Since it is a nonselective cation channel, Ca^2+^ and Na^+^ can cross the TRPA1 channel, which results in membrane depolarization and action potential discharge ([@B110]). The TRPA1 channel has been demonstrated to play a pivotal role in mediating a series of pathophysiological reactions, including pain, inflammation, itching, and tissue injury and repair ([@B10]; [@B67]; [@B97]).

Initially, the TRPA1 channel was thought to be predominately expressed in the sensory neurons of the nodose ganglia, dorsal root ganglia, and trigeminal ganglia ([@B85]; [@B65]), as well as in hair cells ([@B19]; [@B63]). In recent years, various researchers have demonstrated that the TRPA1 channel is widely expressed in nonneuronal cells, such as lung fibroblasts ([@B61]; [@B64]), alveolar epithelial cells ([@B64]), cardiomyocytes ([@B6]), cardiac fibroblasts ([@B70]), arterial endothelial cells (ECs) ([@B77]), pancreatic beta cells ([@B15]), enterochromaffin cells ([@B68]), odontoblasts ([@B27]), and T cells ([@B12]).

The TRPA1 channel responds to a wide range of agonists, including pungent natural compounds, such as allyl isothiocyanate (AITC), cinnamaldehyde, and allicin ([@B9]; [@B38]; [@B52]); ambient toxins, such as acrolein and nicotine ([@B4]; [@B88]); anesthetic agents, such as propofol and lidocaine ([@B49]; [@B100]); chemical compounds, such as ASP-7663 and optovin ([@B43]; [@B42]); and a range of endogenous agonists, such as oxidized lipids, nitric oxide (NO), and hydrogen sulfide (H~2~S) ([@B3]; [@B26]). Both intracellular and extracellular Ca^2+^ can directly activate the channel, whose activation can be further strengthened by agonists ([@B109]; [@B96]). However, the effect of temperature on the activation of the TRPA1 channel is controversial. Some researchers have demonstrated that the TRPA1 channel could be activated by noxious cold stimuli (temperature of \<17°C) ([@B85]; [@B21]), whereas other studies showed that cold does not activate the TRPA1 channel or that the cold-induced increase in intracellular Ca^2+^ indirectly activates the TRPA1 channel ([@B109]). Recent studies have indicated that the TRPA1 channel is activated by several substances that are produced during oxidative stress, such as hydrogen peroxide (H~2~O~2~), 4-hydroxynonenal (4-HNE), 4-oxononenal (4-ONE), 4-hydroxyhexenal (4-HHE), and 15-deoxy-delta(12,14)-prostaglandin J(2) (\[15d-PGJ(2)\]) ([@B93]; [@B3]; [@B90]). In addition, frequently used TRPA1 agonists are listed in [**Table 1**](#T1){ref-type="table"}.

###### 

TRPA1 agonists.

  --------------------------------------------------------------------------------------------------------------------
  Agonists                                                    Source              EC50                     Citations
  ----------------------------------------------------------- ------------------- ------------------------ -----------
  Allyl isothiocyanate                                        Mustard             33 μM (mice)             [@B9]

  (AITC)                                                                          11 ± 1 μM (rat)          [@B52]

  Cinnamaldehyde (CA)                                         Cinnamon            100 μM (mice)            [@B9]

  Allicin                                                     Garlic              1.9 μM (human)           [@B38]

                                                                                  1.3 μM (mice)            

  Nicotine                                                    Tobacco             10 μM (mice)             [@B88]

  Propofol                                                    Anesthetic agents   17 μM (mice)             [@B100]

  Lidocaine                                                   Anesthetic agents   24.0 ± 0.6 mM (human)\   [@B49]
                                                                                  5.7 ± 0.2 μM (rat)       

  ASP-7663                                                    Synthetic           0.51 μM (human)          [@B43]

                                                                                  0.50 μM (mice)           

                                                                                  0.54 μM (rat)            

  Optovin                                                     Synthetic.          2 μM (mice)              [@B42]

  Hydrogen peroxide (H~2~O~2~)                                Oxidative stress    230 μM (mice)            [@B3]

  4-Hydroxynonenal (4-HNE)                                    Oxidative stress    19.9 μM (mice)           [@B3]

  4-Oxononenal (4-ONE)                                        Oxidative stress    1.9 μM (mice)            [@B3]

  4-Hydroxyhexenal (4-HHE)                                    Oxidative stress    38.9 μM (mice)           [@B3]

  15-Deoxy-delta(12,14)-prostaglandin J(2) (\[15d-PGJ(2)\])   Oxidative stress    5.6 μM (mice)            [@B3]
  --------------------------------------------------------------------------------------------------------------------

Many chemicals, such as ruthenium red, amiloride, camphor, and menthol, have been shown to block this channel, but they lack specificity. Moreover, small-molecule compounds, such as HC-030031 ([@B55]) and AP-18 ([@B74]; [@B20]), are primary inhibitors that specifically bind to the channel and have been widely used to study TRPA1 channel-mediated pharmacology *in vitro* and *in vivo*. Recently, some researchers have reported additional TRPA1 antagonists with highly selectivity and pharmaceutical properties, including A-967079 ([@B16]), TCS-5861528 ([@B99]), compound 10 ([@B18]), and compound 31 ([@B80]). These new-generation TRPA1 channel antagonists will be valuable for exploring the function and therapeutic utility of TRPA1. Frequently used TRPA1 inhibitors are listed in [**Table 2**](#T2){ref-type="table"}.

###### 

TRPA1 antagonists.

  --------------------------------------------------------------------------
  Agonists      Structures                   IC50                Citations
  ------------- ---------------------------- ------------------- -----------
  HC-030031     Xanthine derivative          6.2 μM (human)\     [@B55]
                                             7.6 μM (rat)        

  AP-18         Oxime                        3.1 μM (human)\     [@B74]\
                                             8.8 μM (rat)\       [@B20]
                                             4.5 μM (mice)       

  A-967079      Oxime                        0.067 μM (human)\   [@B16]
                                             0.289 μM (rat)      

  TCS-5861528   Xanthine derivative          14.3 μM (human)     [@B99]

  Compound 10   Xanthine derivative          0.17 μM (human)\    [@B18]
                                             0.056 μM (rat)      

  Compound 31   Imidazopyridine derivative   0.015 μM (human)\   [@B80]
                                             0.089 μM (rat)      
  --------------------------------------------------------------------------

Previous studies have demonstrated that the TRPA1 channel is also widely expressed in the cardiovascular system and is involved in regulating intracellular Ca^2+^ concentrations ([@B70]; [@B6]). In this review, we summarize the potential involvement of the TRPA1 channel in modulating pathophysiologic conditions, including atherosclerosis, heart failure, myocardial ischemia--reperfusion injury (IRI), myocardial fibrosis, arrhythmia, vasodilation, and hypertension ([**Table 3**](#T3){ref-type="table"}).

###### 

Role of the TRPA1 channel in the cardiovascular system.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diseases              Animals                                                                       Cellular localization                         Effects                                                                                                                                                                                                         Mechanisms                                                              Citations
  --------------------- ----------------------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------
  Atherosclerosis       Male C57BL/6, apoE^−/−^ and apoE^−/−^TRPA1^−/−^ mice (8 weeks old)            Macrophages                                   AITC (10 mg/kg/d, 4 weeks, i.g.) suppresses atherosclerosis; HC-030031 (10 mg/kg/d, 4 weeks, i.g.) and TRPA1 knockout exacerbate atherosclerosis                                                                Cholesterol metabolism and inflammation in macrophages                  [@B107]

  Heart failure         Male C57BL/6 mice (8--10 weeks old)                                           Cardiomyocytes\                               HC-030031 (10 mg/kg/d, 4 weeks, i.g.) and TCS-5861528 (3 mg/kg/d, 4 weeks, i.g.) ameliorate cardiac hypertrophy and heart failure                                                                               Inhibits Ca^2+^-dependent signal pathways and macrophage polarization   [@B98]
                                                                                                      and macrophages                                                                                                                                                                                                                                                                                                                       

  Myocardial IRI        Male Sprague-Dawley rats (8--10 weeks old)                                    Cardiomyocytes                                ASP-7663 (3 mg/kg *in vivo* and 3 μM *in vitro*) and AP-18 (1 mg/kg *in vivo* and 1 mM *in vitro*) reduce myocardial injury, but cinnamaldehyde (0.01 mg/kg *in vivo*) did not affect myocardial infarct size   Pain management and anti-inﬂammatory drugs                              [@B51]

                        Male C57BL/6 and TRPA1^−/−^ mice (12--16 weeks old)                           Cardiomyocytes                                TRPA1 knockout reduces infarct size                                                                                                                                                                             Reduces Ca^2+^ overload                                                 [@B17]

  Myocardial fibrosis   --                                                                            Human adult ventricular cardiac fibroblasts   HC-030031 (100 μM) and siRNA targeting the TRPA1 channel inhibit methylglyoxal-induced (300 µM) proliferation of cardiac fibroblasts                                                                            Inhibits Ca^2+^ entry                                                   [@B70]

  Arrhythmia            Female B6129 mice (19--21 weeks old) and TRPA1^−/−^ mice (21--28 weeks old)   --                                            Acrolein (537 ppm, 8 times/4 weeks, inhalation) increases heart rate variability and myocardial desynchrony in B6129 mice but not in TRPA1^−/−^ mice                                                            Influence the autonomic nervous system                                  [@B92]

                        Female C57BL/6 and TRPA1^−/−^ mice (15--30 weeks old)                         --                                            TRPA1 knockout decreases acrolein-induced (3 ppm, 3 h) heart rate variability and arrhythmias                                                                                                                   Cardiac autonomic function                                              [@B46] [@B45]

                        Male spontaneously hypertensive rats (18--20 weeks old)                       --                                            HC-030031 (5 mg/kg, i.p.) reduces diesel exhaust (32 ppm, 4 h)- and aconitine (1.5 mg/kg, i.p.)-induced ventricular arrhythmias                                                                                 Restrains the activity of sympathetic and autonomic imbalance           [@B34]

                        Male Sprague-Dawley rats (15 weeks old)                                       --                                            AITC (30 mM) inhalation causes bradycardia atrioventricular blockade and prolonged PR intervals                                                                                                                 Activates the vagus nerve                                               [@B36]

  Vasodilation          Female CD1, C57BL/6, CGRP^−/−^, TRPV1^−/−^, and TRPA1^−/−^ mice               --                                            4-ONE (1--30 nmol, intraplantar injection) triggers a vasodilation response, but not in TRPA1^−/−^ mice                                                                                                         TRPA1-dependent neurogenic vasodilatation                               [@B33]

                        Male Sprague-Dawley rats                                                      Trigeminal root ganglia neurons               AITC (100 μM, intranasal administration) and acrolein (30 μM, intranasal administration) increase cerebral blood flow, but the effect is blocked by HC-030031 (50 μM, intranasal administration)                Neurogenic vasodilation                                                 [@B44]

                        Male CD1, CGRP^−/−^, TRPV1^−/−^, and TRPA1^−/−^ mice (8--12 weeks old)        --                                            Cinnamaldehyde (1%--30%) increases the blood flow, but not in HC-030031 (100 mg/kg)-treated and TRPA1 knockout mice                                                                                             Neurogenic vasodilation                                                 [@B7]

                        Male Sprague-Dawley rats                                                      Endothelial cells                             AITC-induced (3--100 μM) cerebral artery dilation was abolished by the administration of HC-030031 (3 μM)                                                                                                       Endothelium-dependent vasodilation                                      [@B25]

                        Adolescent rats                                                               Endothelial cells                             AITC (15--60 μM) evokes graded cerebral artery vasodilation                                                                                                                                                     Endothelium-dependent vasodilation                                      [@B77]

  Hypertension          Male C57BL/6 and TRPA1^−/−^ mice (8--12 weeks old)                                                                          Conscious C57BL/6 and TRPA1^−/−^ mice have similar basal blood pressures and heart rates                                                                                                                        --                                                                      [@B13]

                        CD1, CGRP^−/−^, TRPV1^−/−^, and TRPA1^−/−^ mice                               --                                            Cinnamaldehyde (80--320 μM/kg) induces a transient hypotensive response followed by a sustained hypertensive response                                                                                           Autonomic system reflexes                                               [@B76]

                        Male Sprague-Dawley rats (15 weeks old)                                       --                                            AITC (30 mM) induces a transient hypertensive response followed by a prolonged hypotensive response                                                                                                             Autonomic system reflexes                                               [@B36]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Role of the Trpa1 Channel in the Cardiovascular System {#s2}
======================================================

Atherosclerosis {#s2_1}
---------------

Atherosclerosis and its complications remain the leading causes of morbidity and mortality in developed countries ([@B58]; [@B83]). Atherosclerosis, characterized by the hardening of the arterial wall and the narrowing of the arterial lumen, is considered a chronic inflammatory disease that results from lipid metabolism dysfunction, smooth muscle cell proliferation, and cholesterol-laden macrophage accumulation ([@B41]; [@B59]; [@B103]). Evidence supports the idea that macrophages are the dominant immune cells and play critical roles in the development of atherosclerosis. During the early stages of atherosclerosis, the accumulation of lipid-laden macrophages and oxidized low-density lipoprotein (oxLDL) leads to lipid droplet generation in the subendothelial space. Macrophage accumulation and foam cell formation exacerbate the development of unstable plaques and plaque rupture ([@B50]; [@B40]).

As we know, cholesterol homeostasis in macrophage foam cells is regulated by the complex mechanisms underlying oxLDL internalization and cholesterol efflux. In macrophage foam cells, oxLDL internalization is mediated by scavenger receptor transporters, and several macrophage transporters, including ATP-binding cassette subfamily A member 1 (ABCA1) and ABCG1, are responsible for cholesterol efflux. In a mouse high-fat diet-induced atherosclerosis model, TRPA1 was localized mainly in macrophages; TRPA1 channel activation with AITC suppressed the progression of atherosclerosis in apolipoprotein E (apoE)^−/−^ mice, while the protective effect was lost in apoE^−/−^TRPA1^−/−^ mice. Moreover, inhibition of TRPA1 activity exacerbated atherosclerosis and abated cholesterol efflux by suppressing oxLDL-induced cholesterol efflux but did not alter oxLDL internalization ([@B107]). This implied that TRPA1 activation suppressed excessive lipid accumulation by increasing ABC transporter-mediated cholesterol efflux. Inflammatory conditions are also a key event an implicated in the progression of atherosclerosis. The author also reported that AITC administration prevented TNF-α-induced macrophage inflammation. Thus, activation of the macrophage TRPA1 channel suppressed atherosclerosis by inhibiting cholesterol efflux and the inflammatory response. In all, these data indicate that pharmacological activation of the TRPA1 channel may have therapeutic value to prevent or treat atherosclerosis.

The existing research is very creative and interesting, but many crucial points still need consideration. Macrophage-mediated cholesterol metabolism and proinflammatory cytokine secretion are central steps in the initiation and progression of atherosclerosis. While there is considerable knowledge on the functions of Ca^2+^ influx from the endothelium and macrophages in atherosclerosis, less is known about the molecular mechanisms by which the TRPA1 channel regulates the formation of macrophage-derived foam cells that directly or indirectly depend on Ca^2+^ influx. Moreover, the macrophage number, macrophage phenotype, macrophage apoptosis, and lesion autophagy are also important determinants of atherosclerosis progression. Whether the TRPA1 channel modulates both the recruitment and polarization of macrophages toward a pro- or anti-inflammatory phenotype is unclear. Further studies require the generation of macrophage-specific TRPA1 knockout mice to examine the contribution of the TRPA1 channel to atherogenesis.

Heart Failure {#s2_2}
-------------

Heart failure is a complex and multisystem clinical syndrome that results from impaired ventricular systolic and/or diastolic function ([@B39]). Heart failure is a result of exposure to chronic cardiac stress or injury, including pressure overload, myocardial infarction or ischemia, myocarditis, and inherited diseases ([@B8]; [@B104]). Ca^2+^ is a critical second messenger in cardiac function. It participates in not only in the excitation--contraction coupling and relaxation of the heart but also in a key signal transduction pathway responsible for various cardiovascular diseases ([@B32]). Altered Ca^2+^ homeostasis contributes notably to the pathophysiology of heart failure, and many models of heart failure exhibit deficient Ca^2+^ handling in cardiomyocytes ([@B11]; [@B79]). For example, the Ca^2+^-dependent Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) and calcineurin pathways are centrally involved in mediating pathological hypertrophy and heart failure ([@B57]; [@B2]). While the precise mechanism remains unclear, accumulating evidence suggests that targeting Ca^2+^ homeostasis in failing cardiomyocytes presents a promising new therapeutic approach for improving cardiac function.

Our previously study showed that TRPA1 expression is increased in failing human and mouse hearts ([@B98]). Inhibition of the TRPA1 channel significantly ameliorated cardiac hypertrophy and heart failure by decreasing the increases in heart weight index and ventricular volume and improving cardiac function in transverse aortic constriction-induced pressure overload in mice. In addition, TRPA1 inhibition significantly reduced critical factors involved in heart failure, including calcineurin and CaMKII phosphorylation in mice induced by pressure overload. Another study demonstrated that that TRPA1 activation induced a dose-dependent increase in contractile function and peak \[Ca^2+^\]~i~ in cardiomyocytes but not in cardiomyocytes obtained from TRPA1^−/−^ mice ([@B5]). In addition, the CaMKII inhibitor KN-93 reversed the AITC-induced increase in \[Ca^2+^\]~i~ and contractile function. Based on these studies, it may be suggested that TRPA1 participates in the regulation of heart failure *via* a Ca^2+^-dependent mechanism.

In failing hearts, Ca^2+^ homeostasis is markedly altered, resulting in impaired systolic and diastolic function ([@B54]; [@B79]). Previous research revealed that the TRPA1 channel is present in cardiomyocytes and that TRPA1-mediated Ca^2+^ release contributed to nearly 40% of the overall \[Ca^2+^\]~i~ increase in the physiological state ([@B6]; [@B82]). The links between TRPA1 and heart failure are briefly summarized in [**Figure 1**](#f1){ref-type="fig"}. Pressure overload activates the TRPA1 channel and increases Ca^2+^ influx. The activation of Ca^2+^-dependent pathways, including CaMKII and calcineurin, leads to hypertrophic gene expression and mediates heart failure.

![The role of transient receptor potential ankyrin 1 (TRPA1) in heart failure. TRPA1 channel inhibition decreased Ca^2+^ influx and inhibited Ca^2+^-dependent pathway activation, ultimately ameliorating pressure overload induced-heart failure. CaMKII, Ca^2+^/calmodulin-dependent protein kinase II; HDAC4, histone deacetylase 4; MEF2, myocyte enhancer factor 2; NFAT, nuclear factor of activated T cells.](fphar-10-01253-g001){#f1}

Myocardial IRI {#s2_3}
--------------

Myocardial IRI is a pathological condition that occurs after a critical ischemic period followed by blood supply restoration and reoxygenation that correlates with a deterioration of myocardial function and a marked inflammatory reaction ([@B29]; [@B28]). A variety of pathological processes and mediators, including intracellular Ca^2+^ overload and excess reactive oxygen species (ROS), are proposed to be crucial in myocardial IRI. During ischemia, ion pumps cannot function, resulting in a rise in Ca^2+^, which leads to intracellular Ca^2+^ overload, particularly during reperfusion when oxygen is reintroduced ([@B62]; [@B31]). ROS are produced physiologically by the mitochondrial electron transport chain during respiration, and increased ROS can result in mitochondrial matrix swelling and cell death ([@B62]; [@B108]). Studies have shown substantial interest in developing therapies to prevent myocardial IRI. In particular, site-targeted treatments, such as inhibiting Ca^2+^ overload and reducing ROS accumulation, may improve the protective effect on the stressed myocardium ([@B78]; [@B37]).

The TRPA1 channel is a calcium-permeable nonselective cation channel in the plasma membrane; however, it also functions as a sensor that is activated by ROS and is modulated when intracellular changes in oxygen levels occur, and both factors are important for IRI ([@B95]; [@B75]). However, the role and mechanism of TRPA1 in myocardial IRI are conflicting and are still controversial. In an *in vivo* rat model of myocardial IRI (30 min of ischemia followed by 2 h of reperfusion), the administration of the TRPA1 agonist reduced the myocardial infarct size before ischemia and reperfusion, and TRPA1 channel inhibition also blocked the infarct size-sparing effects of morphine. In isolated cardiomyocytes, the activation of the TRPA1 channel reduced cardiomyocyte cell death and the release of lactate dehydrogenase when activated during reoxygenation ([@B51]). In contrast, global knockout of TRPA1 results in less myocardial injury in a mouse model of IRI (30 min of ischemia followed by 24 h of reperfusion) ([@B17]). In addition, acrolein, an IRI-associated toxin, induced Ca^2+^ overload and hypercontraction in isolated cardiomyocytes, which were significantly ameliorated by TRPA1 inhibitor. These studies are contradictory, may be because of the exerting differential effects, TRPA1 in cardiac myocytes, vascular cells, and sensory neurons, which eliminates its function leads to variable effects on IRI. Therefore, a genetically modified mouse model with cell-specific deletion (or targeted inhibition) of TRPA1 in cardiomyocytes will be required to assess the role of myocardial TRPA1 in IRI.

As we known, the sensitivity of the TRPA1 channel to ROS was the greatest among the TRP channels ([@B101]). Moreover, the TRPA1 channel also plays a pivotal role in the maintenance of O~2~ homeostasis ([@B87]). This study found that O~2~ could activate the TRPA1 channel through reversible covalent or oxidative modification of cysteine residues in hyperoxia directly. In addition, prolyl hydroxylases (PHDs) could inhibit TRPA1 channel activity under the condition of normoxia, whereas hypoxia could activate TRPA1 by diminishing the activity of PHDs. Accumulating research has shown that Ca^2+^ can enhance ROS output and generation, which correlates well with metabolic rate. Thus, it will be very interesting to determine the mechanism by which the TRPA1 channel mediates Ca^2+^ homeostasis and redox signaling in myocardial IRI ([**Figure 2**](#f2){ref-type="fig"}).

![The role of TRPA1 in myocardial ischemia--reperfusion injury. Under normoxic conditions, PHDs inhibit TRPA1 channel activity. Under hyperoxic conditions, O~2~ directly activates the TRPA1 channel through reversible covalent or oxidative modification of cysteine residues. Under hypoxic conditions, the TRPA1 channel was activated by O~2~-dependent inhibition relief by PHD-mediated hydroxylation of a proline residue. The TRPA1 channel participates in the development of myocardial ischemia--reperfusion injury by regulating Ca^2+^ overload and ROS. PHD, prolyl hydroxylases; Cys, cysteine residue; ROS, reactive oxygen species.](fphar-10-01253-g002){#f2}

Myocardial Fibrosis {#s2_4}
-------------------

Myocardial fibrosis is associated with cardiac fibroblast overproliferation and excessive extracellular matrix (ECM) protein accumulation in the myocardial interstitium ([@B81]; [@B106]). Cardiac fibroblasts are activated in response to a variety of pathological stimuli, such as myocardial injury, pressure overload, and failed repair. Cardiac fibroblasts are the main producers of ECM and play an important role in cell signaling and fibrotic responses ([@B105]; [@B60]). Accumulating evidence has demonstrated that Ca^2+^-dependent signaling is essential for the proliferation and differentiation of cardiac fibroblasts and ECM production ([@B35]; [@B105]). However, Ca^2+^-permeable channels in coordination with Ca^2+^-dependent signaling in cardiac fibroblasts are not fully understood. Thus, understanding the molecules responsible for Ca^2+^-dependent signaling in cardiac fibroblasts will provide novel targets for antifibrotic strategies.

Methylglyoxal (MG), a highly reactive dicarbonyl compound, is a metabolic intermediate of glycolysis that can activate TRPA1. MG can confer deleterious cardiovascular effects, which are associated with the activation of fibrosis ([@B22]; [@B86]). In an *in vitro* study, TRPA1 was expressed in human adult ventricular cardiac fibroblasts, and inhibiting TRPA1 channel activity reduced MG-induced Ca^2+^ influx. Moreover, inhibition of TRPA1 suppressed MG-induced fibroblast proliferation and increased α-smooth muscle actin expression. In this study, the TRPA1-mediated Ca^2+^-dependent signaling pathway was suggested to be required for MG-induced cell cycle progression and differentiation in human cardiac fibroblasts ([@B70]). Another study also demonstrated that inhibition of the TRPA1 channel attenuated fibrosis and inflammation by attenuating TGF-β1 signaling cascades in ocular fibroblasts ([@B71]). Taken together, these studies indicated that the TRPA1 channel may serve as a potential novel therapeutic target for fibrotic responses.

In recent years, the importance of TRP channels in regulating Ca^2+^ signaling and cardiac fibrogenesis has been recognized ([@B91]). Inhibition of the TRPM7 channel reduced the proliferation and differentiation of cardiac fibroblasts and ECM production ([@B23]). In addition, the TRPC3 channel functions as a critical mediator in myocardial fibrosis in coordination with Ca^2+^ signaling and ROS production ([@B69]). Compared with most other TRP channels, the TRPA1 channel has high Ca^2+^ permeability ([@B110]). As the sole member of the TRPA subfamily, the TRPA1 channel could be important in causing cardiac fibrosis. Thus, further studies are required to clarify the molecular mechanisms underlying the regulation of myocardial fibrosis by the TRPA1 channel.

Arrhythmia {#s2_5}
----------

Common air pollution is composed of particulate matter and gaseous pollutants, such as ozone, nitrogen oxides, sulfur dioxide, aldehydes, and acrolein. Epidemiological studies have shown that the deleterious effects of noxious irritants and pollutant inhalation occur upon both short-term and long-term exposure. Air pollution can lead to millions of premature deaths worldwide, of which 60%--80% are cardiovascular diseases. In fact, exposure to air pollutants has been well established as a factor that increases the risk for cardiovascular events, particularly increasing the susceptibility to arrhythmias by altering autonomic nervous system (ANS) balance ([@B14]; [@B47]).

Acrolein is a volatile, unsaturated aldehyde and a toxic combustion product present in tobacco smoke and fires ([@B84]). Recent research reported that exposure to acrolein increased heart rate (HR) variability and the incidence of arrhythmias in WT mice, while these consequences were eliminated in TRPA1^−/−^ mice ([@B46]; [@B45]; [@B92]). Moreover, exposure to diesel exhaust (DE) and aconitine increased sympathetic activation in spontaneously hypertensive rats. Pretreatment of low DE-exposed rats with a TRPA1 inhibitor or sympathetic blockade reduced susceptibility to ventricular arrhythmias ([@B34]). As we know, HR variability is considered to be a marker of ANS imbalance and a risk factor for cardiovascular events. These findings likely indicated that the TRPA1 channel may contribute to the proarrhythmic response by causing sympathetic activation and ANS imbalance.

Other studies showed that the activation of the TRPA1 channel evoked reflex-mediated increases in parasympathetic activity. The application of AITC increased HR and renal sympathetic nerve activity, which were blunted in rats with chronic heart failure ([@B1]). Exposure of conscious rats to AITC caused a significant increase in the incidence of arrhythmic events, which included bradycardia, atrioventricular blockade, and even prolonged PR intervals. Furthermore, such responses to AITC exposure were inhibited by the cholinergic antagonist atropine ([@B36]).

The ANS is composed of the sympathetic and parasympathetic systems located throughout the body, including in the heart, lung, and vasculature system. These sensory nerves are sensitive to multiple stimuli and responsible for maintaining homeostasis by having either excitatory or inhibitory effects. The responses to air pollutants or irritant inhalation are associated with the activation of the sympathetic and parasympathetic systems, which do not function independently and are highly integrated ([@B56]; [@B73]). Previous studies have shown that TRPA1 channels are expressed in primary sensory neurons and that TRPA1 activation results in both afferent and efferent signaling ([@B110]). Different air pollutants and irritants have different effects when TRPA1 is activated, related to the activation of the sympathetic or parasympathetic systems. Thus, considering the complexity of the composition of air pollution and irritants, further studies are needed to identify the roles of the TRPA1 channel in modulating autonomic control of the heart.

Vasodilation {#s2_6}
------------

The vascular system plays essential roles in the transport of gases (such as oxygen and carbon dioxide), nutrients (such as amino acids and electrolytes), and circulating cells in the organism. The vascular system is an exquisitely sculpted vascular network throughout the body and contains multiple components. Among them, ECs and smooth muscle cells act as vital mediators of vascular homeostasis maintenance. In addition, perivascular sensory neurons contribute to the regulation of vascular tone through the release of neuropeptides, such as calcitonin gene-related peptide (CGRP) and substance P ([@B7]).

Recent studies demonstrated the involvement of the TRPA1 channel in the regulation of vasodilation ([@B24]; [@B26]). Intraplantar injection of 4-ONE triggered a significant vasodilation response, which was absent in TRPA1^−/−^ and CGRP^−/−^ mice ([@B33]). Moreover, AITC and environmental irritants, such as formaldehyde and acrolein, stimulate CGRP release and increase cerebral blood flow, effects that were blocked by TRPA1 and a CGRP receptor antagonist ([@B44]). Topical application of cinnamaldehyde to mouse ears resulted in a marked increase in the blood flow in the skin but not in HC-030031- or nitric oxide synthase (NOS) antagonist-pretreated mice ([@B7]). Based on the findings of these studies, it may be proposed that the activation of the TRPA1 channel could mediate neurogenic vasodilation in the peripheral vasculature and could be mediated by the sensory neuropeptide CGRP and NOS-derived NO.

Other studies also demonstrated that the TRPA1 channel causes vasodilation through an endothelium-dependent mechanism involving Ca^2+^ influx in arterial ECs. Earley and colleagues showed that TRPA1 channel was present in arterial ECs, and the AITC-induced cerebral artery dilation was abolished by TRPA1 inhibition and endothelium disruption. In addition, TRPA1 activation-induced dilation was suppressed by treatment with the small and intermediate conductance Ca^2+^-activated K^+^ channel (K~Ca~) and an inwardly rectifying K^+^ channel (K~IR~) blocker ([@B25]). Moreover, activation of the TRPA1 channel enhanced endothelial Ca^2+^ dynamics primarily through the recruitment of endothelial Ca^2+^ and evoked graded cerebral artery vasodilation ([@B77]).

In summary, the above-mentioned results demonstrated that activation of the TRPA1 channel can elicit peripheral vasodilation and that the main mechanisms underlying this process involve nerve-induced vasodilation and endothelium-dependent vasodilation ([**Figure 3**](#f3){ref-type="fig"}). On the one hand, the increased Ca^2+^ influx *via* TRPA1 activation resulted in hyperpolarization of the endothelial cell plasma membrane. The change in membrane potential occurs to hyperpolarize the vascular smooth muscle cell plasma membrane, resulting in myocyte relaxation. On the other hand, activation of TRPA1 in sensory neurons induces an increase in \[Ca^2+^\]~i~, leading to the release of the neuropeptide CGRP and NOS-derived NO, thus mediating vasodilation.

![The role of TRPA1 in vasodilation. On the one hand, increased Ca^2+^ influx *via* TRPA1 activation results in hyperpolarization of the endothelial cell plasma membrane. The change in membrane potential is occurs to hyperpolarize the vascular smooth muscle cell plasma membrane, resulting in myocyte relaxation. On the other hand, the activation of TRPA1 in sensory neurons induces an increase in \[Ca^2+^\]~i~, leading to the release of the neuropeptide CGRP and NOS-derived NO, thus mediating vasodilation. AITC, allyl isothiocyanate; CA, cinnamaldehyde; 4-ONE, 4-oxo-2-nonenal; CGRP, calcitonin gene-related peptide; NOS, nitric oxide synthase; NO, nitric oxide; K~Ca~, Ca^2+^-activated K^+^ channel; K~IR~, inwardly rectifying K^+^ channel; MEGJs, myoendothelial gap junctions.](fphar-10-01253-g003){#f3}

Hypertension {#s2_7}
------------

Hypertension, characterized by increases in systolic blood pressure and/or diastolic blood pressure, is a common clinical disorder and a major public health issue ([@B72]; [@B102]; [@B89]). Hypertension is also a major risk factor for coronary artery disease, heart failure, stroke, and chronic kidney disease ([@B48]; [@B89]). Despite significant advances in antihypertensive therapy, a substantial proportion of patients have uncontrolled blood pressure. As such, there is a continued need to identify new targets to control blood pressure effectively.

Examination of whole-body TRPA1-deficient mice demonstrated that there was no difference in the baseline mean arterial pressure or HR of WT and TRPA1^−/−^ mice under anesthesia ([@B76]). Conscious C57BL/6 and TRPA1^−/−^ mice have similar morphologic and hemodynamic parameters, including basal blood pressure and HR. In addition, similar blood pressure and HR were also observed after angiotensin II infusion ([@B13]). These studies suggest that mice can maintain basic blood pressure and compensate for TRPA1 deficiency.

Experimental and clinical investigations have tested the key role played by the ANS in modulating cardiovascular functions and controlling blood pressure. In humans and experimental animals, both the increased sympathetic nerve tension and reduced parasympathetic tone activity are associated with and responsible for the appearance and maintenance of hypertension and hypertension-related sequelae ([@B30]; [@B53]). Intravenously injected TRPA1 agonist cinnamaldehyde induced a transient hypotensive response followed by a sustained hypertensive response in anesthetized mice. A lower dose of cinnamaldehyde (80 μM/kg) induced a hypotensive response that was significantly less than that in TRPA1^−/−^ mice. Interestingly, the hypertensive response associated with a higher cinnamaldehyde dose (320 μM/kg) was blunted in TRPA1^−/−^ mice. In addition, the cholinergic antagonist atropine significantly inhibited the hypotensive response to the low dose of cinnamaldehyde. The α-adrenergic blocker prazosin significantly inhibited both the hypotensive and hypertensive responses ([@B76]). Another study showed that inhalation of AITC induced a transient hypertensive response followed by a prolonged hypotensive response in SD rats. Intraperitoneal injection of atropine accentuated the AITC-induced hypertensive response and prevented a hypotensive response. However, pretreatment with terazosin, an α1-adrenergic blocker, prevented the AITC-induced hypertensive response ([@B36]). These data indicate that the TRPA1 channel can also influence changes in blood pressure *via* reflex modulation of the ANS.

Therefore, although mice are able to compensate for TRPA1 deficiency and maintain basic blood pressure, the TRPA1 channel can also influence changes in blood pressure *via* reflex modulation of the ANS. Given the diverse activation mechanisms of the TRPA1 channel, future studies may uncover more important functions of the channel in blood pressure regulation. Thus, defining the role of the TRPA1 channel in the regulation of blood pressure will provide a new target for future investigations of antihypertensive therapies.

Conclusion {#s3}
==========

The current review described the potential role of the TRPA1 channel in the regulation of the cardiovascular system. The TRPA1 channel is expressed in the cardiovascular system and involved in mediating a series of cardiovascular pathophysiologies. Activation of the TRPA1 channel has a protective effect against the development of atherosclerosis. Furthermore, TRPA1 channel activation elicits peripheral vasodilation and induces a biphasic blood pressure response. However, loss of channel expression or blockade of its activation suppressed heart failure, myocardial IRI, myocardial fibrosis, and arrhythmia. This finding indicates that the TRPA1 channel can modulate cardiovascular diseases in both positive and negative manners. Given the link between the TRPA1 channel and various cardiovascular diseases, it could be an attractive drug target for therapeutic interventions. However, we should also pay attention to the dual functions of the TRPA1 channel when designing clinical experiments. For this reason, more basic research on the function of the TRPA1 channel must be conducted before TRPA1 channel modulators are used in the clinical setting.
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